# US 2025/0154610 A1 · Methods and compositions for detecting candida species > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2025/0154610 A1 - Document ID: US20250154610A1 - Status: Published application - Kind: A1 - Application number: 19/026,092 - Filed: 2025-01-16 - Published: 2025-05-15 - Earliest claimed: 2016-01-04 - Assignees: Gen-Probe Incorporated - Applicants: Gen-Probe Incorporated - Inventors: Angela S. HUDSON; Damon K. GETMAN; Alice JIANG; Barbara EATON - Web page: https://patentgrep.com/patent/US20250154610A1 ## CPC - C12Q 1/6895: for plants, fungi or algae - C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) - C12Q 1/686: Polymerase chain reaction [PCR] - C12Q 1/689: for bacteria - C12Q 2600/112: Disease subtyping, staging or classification - C12Q 2600/16: Primer sets for multiplex assays - C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract Disclosed are methods utilizing specific amplification of Candida sp. target nucleic acid for detecting the presence or absence of Candida sp. in a sample. Also disclosed are corresponding oligomers, including amplification oligomers, capture probes and detection probes, and combinations thereof, as well as corresponding reaction mixtures and kits. ## Claims ### Claim 1 A method for determining the presence or absence of Candida sp. In a sample, the method comprising: (1) contacting a sample, said sample suspected of containing Candida sp., with at least one of a first amplification oligomer combination and a second amplification oligomer combination, wherein (a) the first amplification oligomer combination comprises first and second Candida-specific amplification oligomers for amplifying a first Candida sp. Target nucleic acid region or a second Candida sp. Target nucleic acid region, wherein said first target region corresponds to a region of SEQ ID NO:129 from about nucleotide position 133 or 161 to about nucleotide position 259 and said second region corresponds to a region of SEQ ID NO:130 from about nucleotide position 202 to about nucleotide position 308, and wherein the first and second Candida-specific amplification oligomers respectively comprise first and second Candida-specific target-hybridizing sequences; and (b) the second amplification oligomer combination comprises first and second C. glabrata-specific amplification oligomers for amplifying a third Candida sp. Target nucleic acid region, wherein said third target region corresponds to a region of SEQ ID NO:131 from about nucleotide position 355 to about nucleotide position 554, and wherein the first and second C. glabrata-specific amplification oligomers respectively comprise first and second C. glabrata-specific target-hybridizing sequences; (2) performing an in vitro nucleic acid amplification reaction, wherein any Candida sp. Target nucleic acid, if present in the sample, is used as a template for generating one or more amplification products corresponding to at least one of the first, second, and third target regions; and (3) detecting the presence or absence of the one or more amplification products, thereby determining the presence or absence of Candida sp. In the sample. ### Claim 2 (depends on 1) The method of claim 1, wherein said method comprises contacting the sample with both the first and second amplification oligomer combinations. ### Claim 3 (depends on 2) The method of claim 2, wherein said method is a multiplex method comprising contacting the sample with both the first and second amplification oligomer combinations within the same reaction mixture. ### Claim 4 (depends on 1, 2, 3) The method of any of claims 1 to 3, wherein first Candida-specific target-hybridizing sequence substantially corresponds to the nucleotide sequence of residues 28-46 of SEQ ID NO:9; and/or the second Candida-specific target-hybridizing sequence is (i) a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:132 and that includes at least the sequence of SEQ ID NO:133, (ii) a sequence of from 20 to 23 contiguous nucleotides contained in the sequence of SEQ ID NO:152 and that includes at least the sequence of SEQ ID NO:151, or (iii) a sequence that substantially corresponds to the nucleotide sequence of SEQ ID NO:34. ### Claim 5 (depends on 1, 2, 3, 4) The method of any of claims 1 to 4, wherein the first C. glabrata-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135; and/or the second C. glabrata-specific target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:136 and that includes at least the sequence of SEQ ID NO:137. ### Claim 6 (depends on 4, 5) The method of claim 4 or 5, further comprising contacting the sample with a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence that substantially corresponds to the nucleotide sequence of SEQ ID NO:34. ### Claim 7 (depends on 4, 5) The method of claim 4 or 5, wherein the first Candida-specific target-hybridizing sequence comprises the nucleotide sequence of residues 28-46 of SEQ ID NO:9; the second Candida-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:26, residues 3-22 of SEQ ID NO:74, or SEQ ID NO:34; the first C. glabrata-specific target-hybridizing sequence comprises the nucleotide sequence of residues 28-49 of SEQ ID NO:14; and/or the second C. glabrata-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:12. ### Claim 8 (depends on 4, 5) The method of any of any one of claims 4, 5, and 7, further comprising contacting the sample with a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence comprising the nucleotide sequence of SEQ ID NO:34. ### Claim 9 (depends on 4, 5) The method of any of claims 4, 5, and 7, wherein the first Candida-specific target-hybridizing sequence consists of the nucleotide sequence of residues 28-46 of SEQ ID NO:9; the second Candida-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:26, SEQ ID NO:74, or SEQ ID NO:34; the first C. glabrata-specific target-hybridizing sequence consists of the nucleotide sequence of residues 28-49 of SEQ ID NO:14; and/or the second C. glabrata-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:12. ### Claim 10 (depends on 4, 5, 7) The method of any of claims 4, 5, 7, and 9, further comprising contacting the sample with a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence consisting of the nucleotide sequence of SEQ ID NO:34. ### Claim 11 (depends on 6, 8) The method of claim 6 or 8, wherein the second Candida-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:26. ### Claim 12 (depends on 6, 8) The method of any one of claims 6, 8, and 10, wherein the second Candida-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:26. ### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) The method of any one of claims 1 to 12, wherein at least one of the first Candida-specific amplification oligomer and the first C. glabrata-specific amplification oligomer is a promoter primer or promoter provider further comprising a promoter sequence located 5′ to the respective target hybridizing sequence. ### Claim 14 (depends on 13) The method of claim 13, wherein the promoter sequence is a T7 promoter sequence. ### Claim 15 (depends on 14) The method of claim 14, wherein the promoter sequence has the nucleotide sequence of residues 1-27 of SEQ ID NO:9. ### Claim 16 (depends on 13) The method of claim 13, wherein the first Candida-specific amplification oligomer has the nucleotide sequence of SEQ ID NO:9; and/or the first C. glabrata-specific amplification oligomer has the nucleotide sequence of SEQ ID NO:14. ### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16) The method of any one of claims 1 to 16, further comprising purifying any Candida sp. Target nucleic acid, if present, from other components in the sample before step (2). ### Claim 18 (depends on 17) The method of claim 17, wherein the purifying step comprises contacting the sample with at least one capture probe oligomer comprising a target-hybridizing sequence covalently attached to a sequence or moiety that binds to an immobilized probe. ### Claim 19 (depends on 18) The method of claim 18, wherein the sample is contacted with a first Candida-specific capture probe oligomer and a first C. glabrata-specific capture probe oligomer, wherein the first Candida-specific capture probe oligomer comprises a first Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid, wherein the first C. glabrata-specific capture probe oligomer comprises a first C. glabrata capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the third Candida sp. Target nucleic acid, and wherein each of the first Candida-specific and C. glabrata-specific capture probe target-hybridizing sequences is covalently attached to the sequence or moiety that binds to the immobilized probe. ### Claim 20 (depends on 19) The method of claim 19, wherein the first Candida-specific capture probe target-hybridizing sequence is (i) a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139 or (ii) a sequence of from 15 to 25 contiguous nucleotides contained in the sequence of SEQ ID NO:140 and that includes at least the sequence of SEQ ID NO:141; and/or the first C. glabrata-specific capture probe target-hybridizing sequence is a sequence of from 16 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO:142 and that includes at least the sequence of SEQ ID NO:143 or SEQ ID NO:144. ### Claim 21 (depends on 20) The method of claim 20, further comprising contacting the sample with a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid, and wherein the second Candida-specific capture probe target-hybridizing sequence is a sequence of from 15 to 25 contiguous nucleotides contained in the sequence of SEQ ID NO:140 and that includes at least the sequence of SEQ ID NO:141. ### Claim 22 (depends on 20) The method of claim 20, wherein the first Candida-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-20 of SEQ ID NO:24 or residues 1-17 of SEQ ID NO:66; and/or the first C. glabrata-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-26 of SEQ ID NO:48. ### Claim 23 (depends on 20, 22) The method of claim 20 or 22, further comprising contacting the sample with a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid comprises the nucleotide sequence of residues 1-17 of SEQ ID NO:66. ### Claim 24 (depends on 20, 22) The method of claim 20 or 22, wherein the first Candida-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-20 of SEQ ID NO:24 or residues 1-17 of SEQ ID NO:66; and/or the first C. glabrata-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-26 of SEQ ID NO:48. ### Claim 25 (depends on 20, 22) The method of any one of claims 20, 22, and 24, further comprising contacting the sample with a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence consisting of the nucleotide sequence of residues 1-17 of SEQ ID NO:66. ### Claim 26 (depends on 21, 23) The method of claim 21 or 23, wherein the first Candida-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-20 of SEQ ID NO:24. ### Claim 27 (depends on 21, 23) The method of any one of claims 21, 23, and 25, wherein the first Candida-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-20 of SEQ ID NO:24. ### Claim 28 (depends on 20, 22) The method of any one of claims 20, 22, and 24, wherein the first Candida-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:24 or SEQ ID NO:66; and/or the first C. glabrata-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:48. ### Claim 29 (depends on 21, 23) The method of any one of claims 21, 23, and 25, wherein the second Candida-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:66. ### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29) The method of any one of claims 1 to 29, wherein the detecting step (3) comprises contacting one or more amplification products with a Candida-specific detection probe that specifically hybridizes to the first or second Candida sp. Target region and a C. glabrata-specific detection probe that specifically hybridizes to the third Candida sp. Target region, and detecting the presence or absence of any target-hybridized Candida-specific and/or C. glabrata-specific detection probe. ### Claim 31 (depends on 30) The method of claim 30, wherein the Candida-specific detection probe comprises a Candida-specific detection probe target-hybridizing sequence selected from the group consisting of (A1) a sequence of from 18 to 22 contiguous nucleotides contained in the sequence of SEQ ID NO:145 and that includes at least the sequence of SEQ ID NO:146, (B1) the DNA equivalent or an RNA/DNA chimeric of (A1), and (C1) the full complement of (A1) or (B1); and/or the C. glabrata-specific detection probe comprises a C. glabrata-specific detection probe target-hybridizing sequence selected from the group consisting of (A2) a sequence of from 17 to 23 contiguous nucleotides contained in the sequence of SEQ ID NO:147 and that includes at least the sequence of SEQ ID NO:148, (B2) a sequence that substantially corresponds to the sequence of residues 1-17 of SEQ ID NO:18, (C2) a sequence that substantially corresponds to the sequence of residues 1-20 of SEQ ID NO:21, (D2) the DNA equivalent or an RNA/DNA chimeric of any of (A2)-(C2), and (E2) the full complement of any one of (A2)-(D2). ### Claim 32 (depends on 31) The method of claim 31, wherein the Candida-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 33 (depends on 31, 32) The method of claim 31 or 32, wherein the Candida-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 34 (depends on 31, 32, 33) The method of any one of claims 31 to 33, wherein the Candida-specific detection probe has a sequence selected from the group consisting of the sequence of SEQ ID NO:27, the DNA or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence has a sequence selected from the group consisting of SEQ ID NO:60, SEQ ID NO:45, SEQ ID NO:18, SEQ ID NO:21, the DNA or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 35 (depends on 30, 31, 32, 33) The method of claim any one of claims 30 to 33, wherein each of the Candida-specific and C. glabrata-specific detection probes comprises a label. ### Claim 36 (depends on 35) The method of claim 35, wherein the label is a chemiluminescent label or a fluorescent label. ### Claim 37 (depends on 35) The method of claim 35, wherein the detecting step (3) occurs during the amplifying step (2). ### Claim 38 (depends on 37) The method of claim 37, wherein each of the Candida-specific and C. glabrata-specific detection probes comprises a fluorescent label and a quencher. ### Claim 39 (depends on 38) The method of claim 38, wherein each of the Candida-specific and C. glabrata-specific detection probes is a molecular torch, a molecular beacon, or a TaqMan detection probe. ### Claim 40 (depends on 30, 31, 32, 33) The method of claim of any one of claims 30 to 33, wherein at least one of the Candida-specific and C. glabrata-specific detection probes further comprises a non-target-hybridizing sequence. ### Claim 41 (depends on 40) The method of claim 40, wherein each of the Candida-specific and C. glabrata-specific detection probes is a molecular torch or a molecular beacon. ### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41) The method of any one of claims 1 to 41, wherein the amplification reaction at step (2) is an isothermal amplification reaction. ### Claim 43 (depends on 42) The method of claim 42, wherein the amplification reaction is a transcription-mediated amplification (TMA) reaction. ### Claim 44 (depends on 42, 43) The method of claim 42 or 43, wherein the amplification reaction is a real-time amplification reaction. ### Claim 45 An oligomer combination for determining the presence or absence of Candida sp. In a sample, the oligomer combination comprising: at least one of a first amplification oligomer combination and a second amplification oligomer combination, wherein (a) the first amplification oligomer combination comprises first and second Candida-specific amplification oligomers for amplifying a first Candida sp. Target nucleic acid region or a second Candida sp. Target nucleic acid region, wherein said first target region corresponds to a region of SEQ ID NO:129 from about nucleotide position 133 or 161 to about nucleotide position 259 and said second region corresponds to a region of SEQ ID NO:130 from about nucleotide position 202 to about nucleotide position 308, and wherein the first and second Candida-specific amplification oligomers respectively comprise first and second Candida-specific target-hybridizing sequences; and (b) the second amplification oligomer combination comprises first and second C. glabrata-specific amplification oligomers for amplifying a third Candida sp. Target nucleic acid region, wherein said third target region corresponds to a region of SEQ ID NO:131 from about nucleotide position 355 to about nucleotide position 554, and wherein the first and second C. glabrata-specific amplification oligomers respectively comprise first and second C. glabrata-specific target-hybridizing sequences. ### Claim 46 (depends on 45) The oligomer combination of claim 45, wherein said oligomer combination comprises both the first and second amplification oligomer combinations. ### Claim 47 (depends on 46) The oligomer combination of claim 46, wherein said oligomer combination comprises both the first and second amplification oligomer combinations within the same reaction mixture. ### Claim 48 (depends on 45, 46, 47) The oligomer combination of any of claims 45 to 47, wherein first Candida-specific target-hybridizing sequence substantially corresponds to the nucleotide sequence of residues 28-46 of SEQ ID NO:9; and/or the second Candida-specific target-hybridizing sequence is (i) a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:132 and that includes at least the sequence of SEQ ID NO:133, (ii) a sequence of from 20 to 23 contiguous nucleotides contained in the sequence of SEQ ID NO:152 and that includes at least the sequence of SEQ ID NO:151, or (iii) a sequence that substantially corresponds to the nucleotide sequence of SEQ ID NO:34. ### Claim 49 (depends on 47, 48) The oligomer combination of any of claims 47 to 48, wherein the first C. glabrata-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135; and/or the second C. glabrata-specific target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:136 and that includes at least the sequence of SEQ ID NO:137. ### Claim 50 (depends on 48, 49) The oligomer combination of claim 48 or 49, further comprising a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence that substantially corresponds to the nucleotide sequence of SEQ ID NO:34. ### Claim 51 (depends on 48, 49) The oligomer combination of claim 48 or 49, wherein the first Candida-specific target-hybridizing sequence comprises the nucleotide sequence of residues 28-46 of SEQ ID NO:9; the second Candida-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:26, residues 3-22 of SEQ ID NO:74, or SEQ ID NO:34; the first C. glabrata-specific target-hybridizing sequence comprises the nucleotide sequence of residues 28-49 of SEQ ID NO:14; and/or the second C. glabrata-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:12. ### Claim 52 (depends on 48, 49) The oligomer combination of any of any one of claims 48, 49, and 51, further comprising a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence comprising the nucleotide sequence of SEQ ID NO:34. ### Claim 53 (depends on 48, 49) The oligomer combination of any of claims 48, 49, and 51, wherein the first Candida-specific target-hybridizing sequence consists of the nucleotide sequence of residues 28-46 of SEQ ID NO:9; the second Candida-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:26, SEQ ID NO:74, or SEQ ID NO:34; the first C. glabrata-specific target-hybridizing sequence consists of the nucleotide sequence of residues 28-49 of SEQ ID NO:14; and/or the second C. glabrata-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:12. ### Claim 54 (depends on 48, 49, 51) The oligomer combination of any of claims 48, 49, 51, and 53, further comprising a third Candida-specific amplification oligomer, wherein the first and second Candida-specific amplification oligomers are for amplifying the first Candida sp. Target nucleic acid region and the second Candida-specific target-hybridizing sequence is a sequence of from 15 to 24 contiguous nucleotides contained in the sequence of SEQ ID NO:134 and that includes at least the sequence of SEQ ID NO:135, and wherein the first and third Candida-specific amplification oligomers are for amplifying the second Candida sp. Target region and the third Candida-specific amplification oligomer comprises a third Candida-specific target-hybridizing sequence consisting of the nucleotide sequence of SEQ ID NO:34. ### Claim 55 (depends on 50, 52) The oligomer combination of claim 50 or 52, wherein the second Candida-specific target-hybridizing sequence comprises the nucleotide sequence of SEQ ID NO:26. ### Claim 56 (depends on 50, 52) The oligomer combination of any one of claims 50, 52, and 54, wherein the second Candida-specific target-hybridizing sequence consists of the nucleotide sequence of SEQ ID NO:26. ### Claim 57 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56) The oligomer combination of any one of claims 45 to 56, wherein at least one of the first Candida-specific amplification oligomer and the first C. glabrata-specific amplification oligomer is a promoter primer or promoter provider further comprising a promoter sequence located 5′ to the respective target hybridizing sequence. ### Claim 58 (depends on 57) The oligomer combination of claim 57, wherein the promoter sequence is a T7 promoter sequence. ### Claim 59 (depends on 58) The oligomer combination of claim 58, wherein the promoter sequence has the nucleotide sequence of residues 1-27 of SEQ ID NO:9. ### Claim 60 (depends on 59) The oligomer combination of claim 59, wherein the first Candida-specific amplification oligomer has the nucleotide sequence of SEQ ID NO:9; and/or the first C. glabrata-specific amplification oligomer has the nucleotide sequence of SEQ ID NO:14. ### Claim 61 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60) The oligomer combination of any one of claims 45 to 60, further comprising at least one capture probe oligomer comprising a target-hybridizing sequence covalently attached to a sequence or moiety that binds to an immobilized probe. ### Claim 62 (depends on 61) The oligomer combination of claim 61, wherein the oligomer combination comprises a first Candida-specific capture probe oligomer and a first C. glabrata-specific capture probe oligomer, wherein the first Candida-specific capture probe oligomer comprises a first Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid, wherein the first C. glabrata-specific capture probe oligomer comprises a first C. glabrata capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the third Candida sp. Target nucleic acid, and wherein each of the first Candida-specific and C. glabrata-specific capture probe target-hybridizing sequences is covalently attached to the sequence or moiety that binds to the immobilized probe. ### Claim 63 (depends on 62) The oligomer combination of claim 62, wherein the first Candida-specific capture probe target-hybridizing sequence is (i) a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139 or (ii) a sequence of from 15 to 25 contiguous nucleotides contained in the sequence of SEQ ID NO:140 and that includes at least the sequence of SEQ ID NO:141; and/or the first C. glabrata-specific capture probe target-hybridizing sequence is a sequence of from 16 to 27 contiguous nucleotides contained in the sequence of SEQ ID NO:142 and that includes at least the sequence of SEQ ID NO:143 or SEQ ID NO:144. ### Claim 64 (depends on 63) The oligomer combination of claim 63, further comprising a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid, and wherein the second Candida-specific capture probe target-hybridizing sequence is a sequence of from 15 to 25 contiguous nucleotides contained in the sequence of SEQ ID NO:140 and that includes at least the sequence of SEQ ID NO:141. ### Claim 65 (depends on 63) The oligomer combination of claim 63, wherein the first Candida-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-20 of SEQ ID NO:24 or residues 1-17 of SEQ ID NO:66; and/or the first C. glabrata-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-26 of SEQ ID NO:48. ### Claim 66 (depends on 63, 65) The oligomer combination of claim 63 or 65, further comprising a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence that specifically hybridizes to a target sequence within the first or second Candida sp. Target nucleic acid comprises the nucleotide sequence of residues 1-17 of SEQ ID NO:66. ### Claim 67 (depends on 63, 65) The oligomer combination of claim 63 or 65, wherein the first Candida-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-20 of SEQ ID NO:24 or residues 1-17 of SEQ ID NO:66; and/or the first C. glabrata-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-26 of SEQ ID NO:48. ### Claim 68 (depends on 63, 65) The oligomer combination of any one of claims 63, 65, and 67, further comprising a second Candida-specific capture probe oligomer, wherein the first Candida-specific capture probe target-hybridizing sequence is a sequence of from 16 to 21 contiguous nucleotides contained in the sequence of SEQ ID NO:138 and that includes at least the sequence of SEQ ID NO:139, and wherein the second Candida-specific capture probe oligomer comprises a second Candida-specific capture probe target-hybridizing sequence consisting of the nucleotide sequence of residues 1-17 of SEQ ID NO:66. ### Claim 69 (depends on 64, 66) The oligomer combination of claim 64 or 66, wherein the first Candida-specific capture probe target-hybridizing sequence comprises the nucleotide sequence of residues 1-20 of SEQ ID NO:24. ### Claim 70 (depends on 64, 66) The oligomer combination of any one of claims 64, 66, and 68, wherein the first Candida-specific capture probe target-hybridizing sequence consists of the nucleotide sequence of residues 1-20 of SEQ ID NO:24. ### Claim 71 (depends on 63, 65) The oligomer combination of any one of claims 63, 65, and 67, wherein the first Candida-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:24 or SEQ ID NO:66; and/or the first C. glabrata-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:48. ### Claim 72 (depends on 64, 66) The oligomer combination of any one of claims 64, 66, and 68, wherein the second Candida-specific capture probe oligomer has the nucleotide sequence of SEQ ID NO:66. ### Claim 73 (depends on 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72) The oligomer combination of any one of claims 45 to 72, further comprising a Candida-specific detection probe that specifically hybridizes to the first or second Candida sp. Target region and a C. glabrata-specific detection probe that specifically hybridizes to the third Candida sp. Target region. ### Claim 74 (depends on 73) The oligomer combination of claim 73, wherein the Candida-specific detection probe comprises a Candida-specific detection probe target-hybridizing sequence selected from the group consisting of (A1) a sequence of from 18 to 22 contiguous nucleotides contained in the sequence of SEQ ID NO:145 and that includes at least the sequence of SEQ ID NO:146, (B1) the DNA equivalent or an RNA/DNA chimeric of (A1), and (C1) the full complement of (A1) or (B1); and/or the C. glabrata-specific detection probe comprises a C. glabrata-specific detection probe target-hybridizing sequence selected from the group consisting of (A2) a sequence of from 17 to 23 contiguous nucleotides contained in the sequence of SEQ ID NO:147 and that includes at least the sequence of SEQ ID NO:148, (B2) a sequence that substantially corresponds to the sequence of residues 1-17 of SEQ ID NO:18, (C2) a sequence that substantially corresponds to the sequence of residues 1-20 of SEQ ID NO:21, (D2) the DNA equivalent or an RNA/DNA chimeric of any of (A2)-(C2), and (E2) the full complement of any one of (A2)-(D2). ### Claim 75 (depends on 74) The oligomer combination of claim 74, wherein the Candida-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 76 (depends on 74, 75) The oligomer combination of claim 74 or 75, wherein the Candida-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 77 (depends on 74, 75, 76) The oligomer combination of any one of claims 74 to 76, wherein the Candida-specific detection probe has a sequence selected from the group consisting of the sequence of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing; and/or the C. glabrata-specific detection probe target-hybridizing sequence has a sequence selected from the group consisting of SEQ ID NO:60, SEQ ID NO:45, SEQ ID NO:18, SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 78 (depends on 73, 74, 75, 76) The oligomer combination of claim any one of claims 73 to 76, wherein each of the Candida-specific and C. glabrata-specific detection probes comprises a label. ### Claim 79 (depends on 78) The oligomer combination of claim 78, wherein the label is a chemiluminescent label or a fluorescent label. ### Claim 80 (depends on 78) The oligomer combination of claim 78, wherein each of the Candida-specific and C. glabrata-specific detection probes comprises a fluorescent label and a quencher. ### Claim 81 (depends on 80) The oligomer combination of claim 80, wherein each of the Candida-specific and C. glabrata-specific detection probes is a molecular torch, a molecular beacon, or a TaqMan detection probe. ### Claim 82 (depends on 73, 74, 75, 76) The oligomer combination of claim of any one of claims 73 to 76, wherein at least one of the Candida-specific and C. glabrata-specific detection probes further comprises a non-target-hybridizing sequence. ### Claim 83 (depends on 82) The oligomer combination of claim 82, wherein each of the Candida-specific and C. glabrata-specific detection probes is a molecular torch or a molecular beacon. ### Claim 84 A detection probe for detecting a Candida sp. Target nucleic acid, wherein said detection probe is a Candida-specific detection probe comprising a Candida-specific detection probe target-hybridizing sequence selected from the group consisting of (A1) a sequence of from 18 to 22 contiguous nucleotides contained in the sequence of SEQ ID NO:145 and that includes at least the sequence of SEQ ID NO:146, (B1) the DNA equivalent or an RNA/DNA chimeric of (A1), and (C1) the full complement of (A1) or (B1), or a C. glabrata-specific detection probe comprising a C. glabrata-specific detection probe target-hybridizing sequence selected from the group consisting of (A2) a sequence of from 17 to 23 contiguous nucleotides contained in the sequence of SEQ ID NO:147 and that includes at least the sequence of SEQ ID NO:148, (B2) a sequence that substantially corresponds to the sequence of residues 1-17 of SEQ ID NO:18, (C2) a sequence that substantially corresponds to the sequence of residues 1-20 of SEQ ID NO:21, (D2) the DNA equivalent or an RNA/DNA chimeric of any of (A2)-(C2), and (E2) the full complement of any one of (A2)-(D2). ### Claim 85 (depends on 84) The detection probe of claim 84, wherein the Candida-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing, or the C. glabrata-specific detection probe target-hybridizing sequence comprises a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 86 (depends on 84, 85) The detection probe of claim 84 or 85, wherein the Candida-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-22 of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing, or the C. glabrata-specific detection probe target-hybridizing sequence consists of a sequence selected from the group consisting of the sequence of residues 1-17 of SEQ ID NO:60, the sequence of residues 1-23 of SEQ ID NO:45, the sequence of residues 1-17 of SEQ ID NO:18, the sequence of residues 1-20 of SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 87 (depends on 84, 85, 86) The detection probe of any one of claims 84 to 86, wherein the Candida-specific detection probe has a sequence selected from the group consisting of the sequence of SEQ ID NO:27, the DNA equivalent or an RNA/DNA chimeric thereof, and the full complement of any of the foregoing, or the C. glabrata-specific detection probe target-hybridizing sequence has a sequence selected from the group consisting of SEQ ID NO:60, SEQ ID NO:45, SEQ ID NO:18, SEQ ID NO:21, the DNA equivalent or an RNA/DNA chimeric of any of the foregoing, and the full complement of any of the foregoing. ### Claim 88 (depends on 84, 85, 86) The detection probe of claim any one of claims 84 to 86, wherein the detection probe comprises a label. ### Claim 89 (depends on 88) The detection probe of claim 88, wherein the label is a chemiluminescent label or a fluorescent label. ### Claim 90 (depends on 88) The detection probe of claim 88, wherein the detection probe comprises a fluorescent label and a quencher. ### Claim 91 (depends on 90) The detection probe of claim 90, wherein the detection probe is a molecular torch, a molecular beacon, or a TaqMan detection probe. ### Claim 92 (depends on 84, 85, 86) The detection probe of claim of any one of claims 84 to 86, wherein the detection probe further comprises a non-target-hybridizing sequence. ### Claim 93 (depends on 92) The detection probe of claim 92, wherein the detection probe is a molecular torch or a molecular beacon.